SCHEMBL6734646

SCHEMBL6734646

Cc1cc(-c2ccc(C(=O)N3CCN(S(=O)(=O)N4Cc5ccc(Cl)cc5C4)CC3)cc2)cc[n+]1[O-]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 5/20 0.45
POLB P06746 2/20 0.44
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
CMA1 P23946 1/20 0.40
LMNA P02545 2/20 0.39
SLC6A7 Q99884 2/20 0.39
SLC6A3 Q01959 1/20 0.39
TSHR P16473 1/20 0.39
MAPKAPK2 P49137 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
KLK1 P06870 1/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6725145 0.89 F10 (0.44) F10POLBKMT2AMEN1CMA1
SCHEMBL6726691 0.87 F10 (0.38) F10POLBLMNATSHR
SCHEMBL6735703 0.84 LSS (0.47) F10POLBKMT2AMEN1LMNA
SCHEMBL6725899 0.83 POLB (0.42) F10POLBKMT2AMEN1CMA1
SCHEMBL6737632 0.82 MET (0.46) F10POLBKMT2AMEN1LMNA
SCHEMBL6730095 0.81 SLC6A7 (0.47) F10POLBKMT2AMEN1LMNA
SCHEMBL6197475 0.81 F10 (0.58) F10KMT2AMEN1
SCHEMBL6730433 0.81 LSS (0.54) F10POLBKMT2AMEN1LMNA
SCHEMBL6729142 0.77 F10 (0.66) F10KLK1
SCHEMBL6735702 0.77 F10 (0.41) F10LMNASLC6A7SLC6A3KLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 F10 19/4885POLB 1782/4885KMT2A 923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.